Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 641-651
© 2001 The British Society for Antimicrobial Chemotherapy

Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections

Ellie J. C. Goldsteina,b,*, Diane M. Citrona, C. Vreni Merriama, Yumi A. Warrena, Kerin Tyrrella and Helen Fernandeza

a R. M. Alden Research Laboratory, Santa Monica-UCLA Medical Center, 2021 Santa Monica Boulevard, Suite 740, East Santa Monica, CA 90404; b UCLA School of Medicine, Los Angeles, CA 90073, USA

We studied the comparative in vitro activity of ertapenem, a new carbapenem, against 240 aerobic and 180 anaerobic recent clinical bite isolates using an agar dilution method and an inoculum of 104 cfu/spot for aerobes and 105 cfu/spot for anaerobes. Ertapenem inhibited 410/420 (98%) of the isolates tested at 4 mg/L with only 4/5 Campylobacter gracilis and 1/3 Campylobacter rectus strains requiring 16 mg/L for inhibition. Ertapenem was only moderately active (MIC 8 mg/L) against 4/6 Enterococcus faecalis and 1/11 Staphylococcus epidermidis strains. All Pasteurella multocida, Pasteurella septica, Pasteurella canis, Pasteurella dagmatis, Moraxella spp. and EF-4 isolates were inhibited at 0.015 mg/L. MIC90s for other aerobic genera and species were as follows: Corynebacterium spp., 4 mg/L; Staphylococcus aureus, 0.25 mg/L; Staphylococcus epidermidis, 4 mg/L; other coagulasenegative staphylococci, 0.25 mg/L; Streptococcus milleri group, 0.5 mg/L; Eikenella corrodens, 0.03 mg/L; and Bergeyella zoohelcum, 0.5 mg/L. For anaerobes the range of MICs and MIC90s were: Prevotella ssp., 0.015–0.5, 0.125 mg/L; Porphyromonas spp., 0.015–0.03, 0.015 mg/L; Fusobacterium spp., 0.015–0.125, 0.03 mg/L; Bacteroides tectum, 0.03–0.125, 0.125 mg/L; and Peptostreptococcus spp., 0.01–2, 1 mg/L. Ertapenem showed excellent potency against the full range of animal and human bite wound pathogens.

* Corresponding author. Tel: +1-310-315-1511; Fax: +1-310-315-3662; E-mail: EJCGMD{at}aol.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
E. J. C. Goldstein, D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez
Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites
J. Antimicrob. Chemother., September 1, 2002; 50(3): 411 - 420.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.